• Je něco špatně v tomto záznamu ?

Differential association of hyperglucagonemia with C-peptide levels in diabetic ketosis/ketoacidosis and hyperosmolar hyperglycemic state

T. Iida, S. Nii, H. Nishikawa, E. Kodama, H. Imai, M. Hashizume, R. Tadokoro, C. Sugisawa, T. Iizaka, F. Otsuka, S. Nagasaka

. 2026 ; 17 (1) : 1. [pub] 20251123

Status minimální Jazyk angličtina Země Japonsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25025977

Grantová podpora
NV19-09-00125 MZ0 CEP - Centrální evidence projektů

AIMS/INTRODUCTION: Glucagon plays a pivotal role in the development of hyperglycemia in diabetes mellitus. The purpose of this study was to investigate the hypothesis that hyperglucagonemia based on measurements of pancreas-specific glucagon is present in diabetic ketosis/ketoacidosis (DK/DKA) and hyperosmolar hyperglycemic state (HHS), and if so, to explore factors contributing to that hyperglucagonemia. MATERIALS AND METHODS: A total of 109 patients (92 with DK/DKA, and 17 with HHS) were investigated. Pancreas-specific glucagon levels were measured with a sandwich enzyme-linked immunosorbent assay at treatment initiation. The relationships of plasma glucagon levels, serum ketone bodies levels, and endogenous insulin secretion were assessed. The change in plasma glucagon levels after treatment was also assessed. RESULTS: The median plasma glucagon level was significantly higher in the HHS group (142.9 pg/mL) than in the DK/DKA group (63.6 pg/mL). In the DK/DKA group, the plasma glucagon level was positively correlated with the serum ketone bodies level (ρ = 0.55, P < 0.0001), but there was no correlation in the HHS group. In the DK/DKA group, a negative correlation was seen between the plasma glucagon level and the serum C-peptide immunoreactivity (CPR)/plasma glucose ratio in type 1 diabetes patients (n = 26) (ρ = - 0.67, P = 0.0002). In the HHS group, a positive correlation was seen between the plasma glucagon level and the serum CPR/plasma glucose ratio (ρ = 0.71, P = 0.0013). The plasma glucagon level was significantly lower after treatment in both the DK/DKA and HHS groups. CONCLUSIONS: Hyperglucagonemia was found in DK/DKA and HHS with pancreas-specific glucagon measurements. The results suggest that the causes of hyperglucagonemia differ in DK/DKA due to type 1 diabetes mellitus and HHS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13340-025-00852-8.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25025977
003      
CZ-PrNML
005      
20251212152621.0
007      
ta
008      
251210s2026 xr f 000 0|eng||
024    7_
$a 10.1007/s13340-025-00852-8 $2 doi
035    __
$a (PubMed)41292690
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ja
100    1_
$a Iida, Tatsuya $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan $1 https://orcid.org/0009000508210648
245    10
$a Differential association of hyperglucagonemia with C-peptide levels in diabetic ketosis/ketoacidosis and hyperosmolar hyperglycemic state / $c T. Iida, S. Nii, H. Nishikawa, E. Kodama, H. Imai, M. Hashizume, R. Tadokoro, C. Sugisawa, T. Iizaka, F. Otsuka, S. Nagasaka
520    9_
$a AIMS/INTRODUCTION: Glucagon plays a pivotal role in the development of hyperglycemia in diabetes mellitus. The purpose of this study was to investigate the hypothesis that hyperglucagonemia based on measurements of pancreas-specific glucagon is present in diabetic ketosis/ketoacidosis (DK/DKA) and hyperosmolar hyperglycemic state (HHS), and if so, to explore factors contributing to that hyperglucagonemia. MATERIALS AND METHODS: A total of 109 patients (92 with DK/DKA, and 17 with HHS) were investigated. Pancreas-specific glucagon levels were measured with a sandwich enzyme-linked immunosorbent assay at treatment initiation. The relationships of plasma glucagon levels, serum ketone bodies levels, and endogenous insulin secretion were assessed. The change in plasma glucagon levels after treatment was also assessed. RESULTS: The median plasma glucagon level was significantly higher in the HHS group (142.9 pg/mL) than in the DK/DKA group (63.6 pg/mL). In the DK/DKA group, the plasma glucagon level was positively correlated with the serum ketone bodies level (ρ = 0.55, P < 0.0001), but there was no correlation in the HHS group. In the DK/DKA group, a negative correlation was seen between the plasma glucagon level and the serum C-peptide immunoreactivity (CPR)/plasma glucose ratio in type 1 diabetes patients (n = 26) (ρ = - 0.67, P = 0.0002). In the HHS group, a positive correlation was seen between the plasma glucagon level and the serum CPR/plasma glucose ratio (ρ = 0.71, P = 0.0013). The plasma glucagon level was significantly lower after treatment in both the DK/DKA and HHS groups. CONCLUSIONS: Hyperglucagonemia was found in DK/DKA and HHS with pancreas-specific glucagon measurements. The results suggest that the causes of hyperglucagonemia differ in DK/DKA due to type 1 diabetes mellitus and HHS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13340-025-00852-8.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Nii, Sayuri $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
700    1_
$a Nishikawa, Hiroto $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
700    1_
$a Kodama, Eriko $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
700    1_
$a Imai, Hideyuki $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
700    1_
$a Hashizume, Mai $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
700    1_
$a Tadokoro, Rie $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
700    1_
$a Sugisawa, Chiho $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
700    1_
$a Iizaka, Toru $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
700    1_
$a Otsuka, Fumiko $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
700    1_
$a Nagasaka, Shoichiro $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
773    0_
$w def $t Diabetol Int $x 2190-1678 $g Roč. 17, č. 1 (2026), s. 1
856    41
$u https://pubmed.ncbi.nlm.nih.gov/41292690 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y -
990    __
$a 20251210 $b ABA008
999    __
$a min $b bmc $g 2446479 $s 1264175
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2026 $b 17 $c 1 $d 1 $e 20251123 $i 2190-1678 $m Diabetology international $n Diabetol Int $x def
GRA    __
$a NV19-09-00125 $p MZ0
LZP    __
$a AZV-2023-Pubmed-20251210

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...